x
[contact-form-7 404 "Not Found"]

Our Business

Tersan’s XAI Driven Drug Development Platform :
Accelerated Path From Design to Approval
AI Driven Knowledge Integration and Discovery Platform Aiming at Regulatory Strategy
Elara Pharmaceuticals Ltd - Img
Robust, explainable XAI integrates a broad range of clinical and multi-omic data, leading to expedited product approval
Integrating 100,000s parameters, starting with as few as 10s of patients
0
Partnerships
0B
RWE Patients Records
0
Years of experience
0M
Total Investment
We design Precision Medicine Clinical protocols


We can start our process at the pre-clinical
stage or with as few as 10 patients.

We integrate pre-clinical data, data from
past clinical trials when they exist.

Real World Evidence data from our extensive knowledge base in order to identify biomarkers and design a data enriched clinical protocol.

Image - Elara Pharmaceuticals Ltd
We collect & generate data
Elara Pharmaceuticals Ltd - Img
Through our international leading genomic sequencing laboratory partners, we manage the process of acquiring multi-omic data (DNA, RNA, Gut micro biota, single cell RNA expression) immune profiling (FACS) etc. data. We enrich our design using our 160 Million+ Real World Evidence data, including synthetic control arms. The challenge is to analyze and integrate these datasets of diverse patient attributes into logical and actionable “signatures” that support your drug development decisions. Using our KEM® (Knowledge, Extraction, Management) technology, Tersan offers a unique and validated approach to data analysis that guarantees you learn everything you want to know from your data. By working with Ariana, you save money, save time, accelerate your development timelines and preserve patent life. Integrating 100.000s parameters : Robust, eXplainable XAI used to integrate a broad range of clinical and multi-omic data towards precision medicine
Integrate and discover with our XAI Technology​
Using our KEM® Al platform and combined analysis,
we identify:

• Optimal dose

• Companion biomarkers and best responders end-points and surrogate endpoints

• Synergistic drug combinations

• Novel indications
Elara Pharmaceuticals Ltd - Img
Regulatory Strategy
Elara Pharmaceuticals Ltd - Img

Benefiting from over 10 years of close interactions with the FDA,
we transform findings from the KEM® platform into optimal regulatory strategies for accelerated approval

KEM® Technology validated by a large number of partners
Tersan Partners
Recents Articles

Latest Press Release​s

Recent Posts Cancer

09May

Elara Pharmaceuticals Ltd continues to bolster Scientific Advisory Board by adding world-leading Oncologist Pr. Jean-Yves BLAY

by Thomas Turcat,   0 Comments

Elara Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug developme...

Read More
Recent Posts

27Mar

Elara Pharmaceuticals Ltd strengthens SAB with appointment of world-leading Neurologist Jacques Touchon

by Thomas Turcat,   0 Comments

Cambridge, MA, USA and Paris, France, March 27, 2023 – Elara Pharmaceuticals Ltd...

Read More
Alzheimer's

30Nov

CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ​

by Thomas Turcat,   0 Comments

• Phase 1 studies show improvement in cognitive factors, consistent ...

Read More